孤儿药的政策制定及其挑战。 - Suppr

Policymaking for Orphan Drugs and Its Challenges.

作者信息

Rhee Taeho Greg

机构信息

Doctoral candidate in the Department of Pharmaceutical Care and Health Systems in the College of Pharmacy at the University of Minnesota in Minneapolis.

出版信息

AMA J Ethics. 2015 Aug 1;17(8):776-9. doi: 10.1001/journalofethics.2015.17.8.pfor2-1508.

DOI:10.1001/journalofethics.2015.17.8.pfor2-1508

PMID:26270879

Abstract

摘要

相似文献

Policymaking for Orphan Drugs and Its Challenges.

AMA J Ethics. 2015 Aug 1;17(8):776-9. doi: 10.1001/journalofethics.2015.17.8.pfor2-1508.

Lucrative niches: how drugs for rare diseases became lifeline for companies.

Wall St J (East Ed). 2005 Nov 15:A1, A18.

The Orphan Drug Act Revisited.

JAMA. 2019 Mar 5;321(9):833-834. doi: 10.1001/jama.2019.0290.

Policy alternatives for treatments for rare diseases.

CMAJ. 2010 Nov 23;182(17):E787-92. doi: 10.1503/cmaj.081429. Epub 2010 Jul 12.

HHS defends expanded 340B drug discounts.

Mod Healthc. 2014 Jun 16;44(24):9.

A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.

J Public Health Policy. 2010 Dec;31(4):407-20; discussion 420-1. doi: 10.1057/jphp.2010.30.

Orphan drugs and orphan tests in the USA.

Community Genet. 2004;7(4):169-72. doi: 10.1159/000082255.

Regulators adopt more orphan drugs.

Nature. 2014 Apr 3;508(7494):16-7. doi: 10.1038/508016a.

The European rare diseases therapeutic initiative.

PLoS Med. 2005 Sep;2(9):e243. doi: 10.1371/journal.pmed.0020243. Epub 2005 Aug 23.

[Orphan drugs--medications for patients with rare diseases].

Ugeskr Laeger. 2006 Jun 5;168(23):2236-8.

引用本文的文献

Rare disease challenges and potential actions in the Middle East.

Int J Equity Health. 2025 Feb 26;24(1):56. doi: 10.1186/s12939-025-02388-4.

Establishment of a value assessment framework for orphan medicinal products in China.

Orphanet J Rare Dis. 2024 Oct 20;19(1):390. doi: 10.1186/s13023-024-03393-6.

A systematic review of moral reasons on orphan drug reimbursement.

Orphanet J Rare Dis. 2021 Jun 30;16(1):292. doi: 10.1186/s13023-021-01925-y.

A compilation of national plans, policies and government actions for rare diseases in 23 countries.

Intractable Rare Dis Res. 2018 Nov;7(4):213-222. doi: 10.5582/irdr.2018.01085.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Policymaking for Orphan Drugs and Its Challenges.

AMA J Ethics. 2015 Aug 1;17(8):776-9. doi: 10.1001/journalofethics.2015.17.8.pfor2-1508.

Lucrative niches: how drugs for rare diseases became lifeline for companies.

Wall St J (East Ed). 2005 Nov 15:A1, A18.

The Orphan Drug Act Revisited.

JAMA. 2019 Mar 5;321(9):833-834. doi: 10.1001/jama.2019.0290.

Policy alternatives for treatments for rare diseases.

CMAJ. 2010 Nov 23;182(17):E787-92. doi: 10.1503/cmaj.081429. Epub 2010 Jul 12.

HHS defends expanded 340B drug discounts.

Mod Healthc. 2014 Jun 16;44(24):9.

A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.

J Public Health Policy. 2010 Dec;31(4):407-20; discussion 420-1. doi: 10.1057/jphp.2010.30.

Orphan drugs and orphan tests in the USA.

Community Genet. 2004;7(4):169-72. doi: 10.1159/000082255.

Regulators adopt more orphan drugs.

Nature. 2014 Apr 3;508(7494):16-7. doi: 10.1038/508016a.

The European rare diseases therapeutic initiative.

PLoS Med. 2005 Sep;2(9):e243. doi: 10.1371/journal.pmed.0020243. Epub 2005 Aug 23.

[Orphan drugs--medications for patients with rare diseases].

Ugeskr Laeger. 2006 Jun 5;168(23):2236-8.

引用本文的文献

Rare disease challenges and potential actions in the Middle East.

Int J Equity Health. 2025 Feb 26;24(1):56. doi: 10.1186/s12939-025-02388-4.

Establishment of a value assessment framework for orphan medicinal products in China.

Orphanet J Rare Dis. 2024 Oct 20;19(1):390. doi: 10.1186/s13023-024-03393-6.

A systematic review of moral reasons on orphan drug reimbursement.

Orphanet J Rare Dis. 2021 Jun 30;16(1):292. doi: 10.1186/s13023-021-01925-y.

A compilation of national plans, policies and government actions for rare diseases in 23 countries.

Intractable Rare Dis Res. 2018 Nov;7(4):213-222. doi: 10.5582/irdr.2018.01085.

Policymaking for Orphan Drugs and Its Challenges.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献